2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report 2024 13 March 2025 at 4.00 p.m.: Annual General Meeting ALK ...

Ensacove is approved for ALK-positive NSCLC patients who haven't received prior ALK-inhibitors, offering a new first-line treatment option. The eXALT3 trial showed Ensacove significantly improved ...

For safety, the most common adverse effects (AEs) related to ensartinib included rash (67.8%), increased aspartate aminotransferase (37.8%), increased alanine aminotransferase (48.3%), pruritus (26.6% ...

for the treatment of adults with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. In the trial, 290 patients were ...

Opens in a new tab or window The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the ...

NORTH CHARLESTON, S.C. (WCIV) — A large structure fire on Ashley Phosphate Road prompted emergency fire response late Thursday evening, according to the North Charleston Fire Department.

The Tulsa, Oklahoma-based company said in a news release that the completion of MB-6 increases the company's fractionation capacity to more than one million bpd, “reducing the need for third ...